Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Research

• Publication date

  1996-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8758931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS

  1995cited by this paper
• Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

  1995cited by this paper
• Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers.

  1995cited by this paper
• Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL(*)

  1995cited by this paper
• Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

  1995cited by this paper
• The Ras GTPase-activating Protein (GAP) Is an SH3 Domain-binding Protein and Substrate for the Src-related Tyrosine Kinase, Hck (*)

  1995cited by this paper
• Cancer genes and hematopoiesis.

  1994cited by this paper
• Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.

  1994cited by this paper
• Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.

  1994cited by this paper
• Functional and biochemical association of Hck with the LIF/IL‐6 receptor signal transducing subunit gp130 in embryonic stem cells.

  1994cited by this paper
• SH2 and SH3 domains as molecular adhesives: the interactions of Crk and Abl.

  1994cited by this paper
• Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.

  1994cited by this paper
• Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.

  1994cited by this paper
• Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway

  1994cited by this paper
• The effector interactions of p21ras.

  1993cited by this paper
• Granulocyte macrophage‐colony stimulating factor stimulates both association and activation of phosphoinositide 3OH‐kinase and src‐related tyrosine kinase(s) in human myeloid derived cells.

  1993cited by this paper
• Mapping of sites on the Src family protein tyrosine kinases p55blk, p59fyn, and p56lyn which interact with the effector molecules phospholipase C-gamma 2, microtubule-associated protein kinase, GTPase-activating protein, and phosphatidylinositol 3-kinase

  1993cited by this paper
• Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

  1993cited by this paper
• How receptor tyrosine kinases activate Ras.

  1993cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines.

  1992cited by this paper
• Multiple SH2-mediated interactions in v-src-transformed cells

  1992cited by this paper
• Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.

  1992cited by this paper
• Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src

  1992cited by this paper
• Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases.

  1992cited by this paper
• Granulocyte‐Macrophage colony‐stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor‐dependent hematopoietic cell line

  1992cited by this paper
• Clonal succession and deletion of bcr/abl sequences in chronic myelogenous leukemia with recurrent lymphoid blast crisis.

  1991cited by this paper
• GTPase-activating protein interactions with the viral and cellular Src kinases.

  1991cited by this paper
• Delayed thymocyte development induced by augmented expression of p56lck

  1991cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

  1984cited by this paper

• DeepAEG: a model for predicting cancer drug response based on data enhancement and edge-collaborative update strategies

  2024cites this paper
• The Cdc42 effector and non-receptor tyrosine kinase, ACK defines a distinct STAT5 transcription signature in a chronic myeloid leukaemia cell model

  2022cites this paper
• The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation

  2022cites this paper
• Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

  2021cites this paper
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

  2020cites this paper
• Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia

  2019cites this paper
• Membrane anchoring of Hck kinase via the intrinsically disordered SH4-U and lengthscale associated with subcellular localization.

  2019cites this paper
• Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia

  2019cites this paper
• Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly

  2019cites this paper
• Multi-Targeted Approach to Treat DrugResistant CML Using Natural Compounds:A Double Edged Sword

  2018cites this paper
• Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia

  2018influential citation
• The role of protein-tyrosine phosphatases for sensitivity and resistance of CML-cells to tyrosine-kinase inhibitors

  2018cites this paper
• A novel BLK-induced tumor model

  2017cites this paper
• UNIVERSITY OF NAPLES "FEDERICO II" Doctorate School in Advanced Medical and Surgical Therapies XXIX Cycle

  2017cites this paper
• CD99 is a therapeutic target on disease stem cells in myeloid malignancies

  2017cites this paper
• Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation

  2017cites this paper
• The Biology and Pathogenesis of Chronic Myeloid Leukemia

  2016cites this paper
• SIMULTANEOUS INHIBITION OF DRIVER AND EFFECTOR KINASES PROMOTES POTENT GROWTH ARREST OF AML CELLS IN VITRO AND IN VIVO

  2016cites this paper
• Proteogenomic insights into the nature of chemoresistance in Chronic Myelogenous Leukemia

  2015cites this paper
• Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemia

  2015cites this paper
• Src family kinases and their role in hematological malignancies

  2015cites this paper
• Natural course and biology of CML

  2015cites this paper
• Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells

  2015cites this paper
• Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction

  2015cites this paper
• Hck inhibitors as potential therapeutic agents in cancer and HIV infection.

  2015cites this paper
• AXL kinase as a novel target for cancer therapy

  2014cites this paper
• NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

  2014cites this paper
• Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2014cites this paper
• Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia

  2014cites this paper
• Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

  2014cites this paper
• The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia.

  2014cites this paper
• Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.

  2014cites this paper
• Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR–ABL-positive cells

  2013cites this paper
• protein stability in imatinib resistant chronic myelogenous leukemia cells Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl

  2013cites this paper
• Inhibition by imatinib of expression of O-glycan-related glycosyltransferases and tumor-associated carbohydrate antigens in the K562 human leukemia cell line.

  2013cites this paper
• Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line

  2013cites this paper
• chronic myeloid leukemia + BCR-ABL 1 JAK of all trades : JAK 2-STAT 5 as novel therapeutic targets in

  2013cites this paper
• JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.

  2013cites this paper
• Anti-tumor Activity of Novel Compounds Targeting BCR-ABL, c-SRC and BCR-ABLT315I in Chronic Myelogenous Leukemia

  2013cites this paper
• Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

  2013cites this paper
• p210 bcr-abl In Vivo Signalling by Oncoprotein Tyrosine Kinase Protein Tyrosine Phosphatase 1B Antagonizes

  2013cites this paper
• Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.

  2013cites this paper
• Anti-tumor Activity of Novel Compounds Targeting BCR-ABL, c-SRC and BCR-ABL in Chronic Myelogenous Leukemia

  2013cites this paper
• Identification of Hck Inhibitors As Hits for the Development of Antileukemia and Anti‐HIV Agents

  2013cites this paper
• Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models

  2012cites this paper
• Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.

  2012cites this paper
• Investigating allosteric regulation of ABL and BCR-ABL kinases: Implications for small molecule inhibitors

  2012cites this paper
• Targeting the cancer initiating cell: the ultimate target for cancer therapy.

  2012cites this paper
• The Molecular Mechanisms for Maintenance of Cancer Stem Cells in Chronic Myeloid Leukemia: A Dissertation

  2012cites this paper
• 1 Treatment of Chronic Myeloid Leukaemia : Current Practice and Future Prospects

  2012cites this paper
• The response to Histone deacetylase inhibitor in Imatinib resistant, BCR-ABL independent, K562 variant with high levels of phosphorylated P38

  2012cites this paper
• PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells

  2012cites this paper
• SRC a critical signaling mediator in FLT 3 ITD positive AML

  2012cites this paper
• Expression and Activity of Fyn Mediate Proliferation and Blastic Features of Chronic Myelogenous Leukemia

  2012cites this paper
• Peptide-based biosensors and light-activatable proteins: tools for studying cell signaling and developing cancer diagnosis

  2012cites this paper
• Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects

  2012cites this paper
• Role of the Adapter Protein 3BP2 in BCR-ABL-mediated Signal Transduction and Leukemogenesis

  2012influential citation
• Src Inhibitors, PP2 and Dasatinib, Increase Retinoic Acid-Induced Association of Lyn and c-Raf (S259) and Enhance MAPK Dependent Differentiation of Myeloid Leukemia Cells

  2011cites this paper
• A Correction to the Review Titled: “ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity” by J. Colicelli

  2011cites this paper
• Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

  2011cites this paper
• Negative Feedback Mechanisms Controlling Src Signaling Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl

  2011cites this paper
• Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.

  2011cites this paper
• Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

  2011cites this paper
• Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.

  2011cites this paper
• Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?

  2011cites this paper
• Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.

  2011cites this paper
• Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?

  2011cites this paper
• Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis

  2011cites this paper
• Managing resistance in chronic myeloid leukemia.

  2011cites this paper
• Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling

  2011cites this paper
• Investigation into the relevance of BCR-ABL for the survival of cancer stem cells in chronic myeloid leukaemia

  2010cites this paper
• ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity

  2010cites this paper
• Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner*

  2010cites this paper
• in cell lines expressing Bcr-Abl Synergy between imatinib and mycophenolic acid in inducing apoptosis

  2010cites this paper
• Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia

  2010cites this paper
• Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

  2010cites this paper
• Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

  2010cites this paper
• Tyrosine phosphorylation of SHIP promotes its proteasomal degradation.

  2010cites this paper
• From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

  2010cites this paper
• Signaling Targets in Myeloid Leukemias

  2010cites this paper
• c‐Abl and Src‐family kinases cross‐talk in regulation of myeloid cell migration

  2010cites this paper
• Chronic Myeloid Leukemia: Pathophysiology and Therapeutics

  2010cites this paper
• Targeted therapy of chronic myeloid leukemia.

  2010cites this paper
• In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).

  2010cites this paper
• Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro

  2009cites this paper
• The Novel Role for Lyn in Integrin Signaling in Human Disease

  2009cites this paper
• STAT3 contributes to resistance towards BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance in chronic myeloid leukemia cells

  2009cites this paper
• Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.

  2009cites this paper
• Src kinases as therapeutic targets for cancer

  2009cites this paper
• Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia

  2009cites this paper
• Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

  2009cites this paper
• Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

  2009cites this paper
• ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells.

  2009cites this paper
• The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms.

  2009cites this paper
• The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines

  2009cites this paper
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

  2009cites this paper
• Investigating the SRC kinase HCK functions in Chronic Myelogenous Leukemia using chemical genetics methods.

  2009cites this paper
• Bcr-Abl induces autocrine IGF-1 signaling

  2008cites this paper
• Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

  2008cites this paper
• Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.

  2008cites this paper